TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review

Autoimmun Rev. 2022 Aug;21(8):103137. doi: 10.1016/j.autrev.2022.103137. Epub 2022 Jul 6.

Abstract

Background: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the salivary and lacrimal glands associated with sicca syndrome. TAFRO syndrome is a systemic inflammatory disease of unknown cause, characterized by Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, Renal dysfunction and Organomegaly, first reported in 2010 in Japanese patients. Despite their rarity, both conditions have been concurrently reported in several patients during the recent years, hence questioning the existence of shared or related features.

Methods: A systematic review of the literature regarding SjS associated with TAFRO syndrome (SjS-TAFRO) was performed. The 2019 updated Masaki diagnostic criteria were used for TAFRO syndrome and SjS was considered when the diagnosis was mentioned by the authors, necessarily with either anti-Sjogren's Syndrome A (SSA) ± anti-Sjogren's Syndrome B (SSB) antibodies and/or histological evidence of focal lymphocytic sialadenitis.

Results: Ten cases of SjS-TAFRO have been reported in the literature to date. Compared to SjS patients without TAFRO syndrome, these 10 SjS-TAFRO had a lower female predominance (2.3:1 vs 9:1 women to man ratio) and a higher frequency of anti-SSA antibodies (90% vs 70%). All fulfilled the three major Masaki criteria i.e., anasarca, thrombocytopenia, and systemic inflammation. Seven of them (70%) had megakaryocyte hyperplasia or reticulin fibrosis in the bone marrow. Lymph node biopsy was performed in 8 out of 10 cases (80%) and results were consistent with Castleman disease in 6 (75%). Eight of them had developed renal failure (80%) within six months. Nine of them (90%) had organomegaly, with hepatosplenomegaly in 8 cases and splenomegaly alone in 1.

Conclusion: This review brings new insights regarding TAFRO syndrome and suggests it could be a severe manifestation of SjS. The identification of shared abnormal signaling pathways could help in the therapeutic management of both diseases, which face an unmet therapeutic need.

Keywords: Anasarca; Castleman disease; Review; Sjogren's syndrome; TAFRO syndrome; Thrombocytopenia.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Antibodies, Antinuclear
  • Castleman Disease* / complications
  • Castleman Disease* / diagnosis
  • Castleman Disease* / drug therapy
  • Edema / complications
  • Edema / diagnosis
  • Edema / drug therapy
  • Female
  • Fibrosis
  • Humans
  • Male
  • Reticulin
  • Sjogren's Syndrome* / complications
  • Sjogren's Syndrome* / diagnosis
  • Thrombocytopenia* / etiology

Substances

  • Antibodies, Antinuclear
  • Reticulin

Supplementary concepts

  • Multi-centric Castleman's Disease